Madhavagopal Cherukuri, MD
Interventional Cardiology · Phoenix, AZNPI 1104860337
Payments from drug & device makers
Across 259 payments — averaging $626.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$137K
- Amgen$13K
- Medtronic$5K
- Johnson & Johnson$3K
- AstraZeneca$572
- Abiomed$490
- plus $3K from 32 others
What the payments were for
- Speaking & faculty fees$18,00268%
- Travel & lodging$60%
- Food & beverage$8,54032%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 42 | $137,041 |
| Amgen | 32 | $13,266 |
| Medtronic(2 entities) | 75 | $4,607 |
| Johnson & Johnson | 10 | $3,415 |
| AstraZeneca | 11 | $572 |
| Abiomed | 8 | $490 |
| Shockwave Medical, Inc | 2 | $314 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $232 |
| Boston Scientific | 3 | $222 |
| Angiodynamics, Inc. | 2 | $216 |
| Novartis | 8 | $193 |
| Kestra Medical Technology Services, Inc. | 8 | $191 |
| Edwards Lifesciences | 2 | $174 |
| Cvrx, Inc. | 1 | $154 |
| Sanofi | 2 | $151 |
| Penumbra, Inc. | 1 | $130 |
| E.r. Squibb & Sons, L.L.C. | 7 | $128 |
| Boehringer Ingelheim | 4 | $103 |
| Philips North America LLC | 4 | $81 |
| Heartflow, Inc. | 1 | $73 |
| Bayer | 3 | $68 |
| Sanofi-aventis U.S. LLC | 3 | $54 |
| Impulse Dynamics (USA) Inc. | 2 | $51 |
| Pfizer | 2 | $48 |
| Chiesi USA, Inc. | 2 | $45 |
| Bardy Diagnostics, Inc. | 2 | $40 |
| Actelion Pharmaceuticals US, Inc. | 2 | $40 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $34 |
| Biosense Webster, Inc. | 1 | $33 |
| Novo Nordisk | 1 | $25 |
| Siemens Medical Solutions USA, Inc. | 1 | $23 |
| Endotronix, Inc. | 1 | $23 |
| Baxter Healthcare | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Akcea Therapeutics, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| GSK | 1 | $14 |
| Lundbeck LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$12,727
- XARELTO$3,300
- COREVALVE EVOLUT R$2,100
- FARXIGA$362
- Impella$338
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$314
- Micra$282
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$262
- Indigo$260
- CardioMEMS HF System$251
- Barostim Neo System$154
- MitraClip$145
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$144
- LifeVest$141
- CARDIOMEMS$137
- Azure$137
- WATCHMAN Access System$133
- HeartWare HVAD$129
- Assurity Pacemaker$127
- Xience V coronary stent system$123
How this compares
$162,332 in reported general payments places this provider in the 85th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 332 | $432,519 |
| XareltoRivaroxaban | 172 | $224,991 |
| EntrestoSacubitril/Valsartan | 105 | $156,433 |
| Repatha SureclickEvolocumab | 126 | $138,746 |
| FarxigaDapagliflozin Propanediol | 45 | $53,495 |
| Praluent PenAlirocumab | 21 | $30,742 |
| MultaqDronedarone Hcl | 18 | $28,465 |
| Repatha SyringeEvolocumab | 13 | $16,219 |
| BrilintaTicagrelor | 12 | $11,828 |
| Ranolazine ErRanolazine | 39 | $6,916 |
| Nebivolol Hcl | 93 | $6,605 |
| Atorvastatin Calcium | 542 | $5,647 |
| Metoprolol Succinate | 269 | $3,782 |
| Rosuvastatin Calcium | 344 | $3,737 |
| Losartan Potassium | 342 | $3,717 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $48 | $432,519332 claims |
| Johnson & JohnsonXarelto | $3,415 | $224,991172 claims |
| NovartisEntresto | $193 | $156,433105 claims |
| AstraZenecaFarxiga, Brilinta | $572 | $65,32357 claims |
| Sanofi-aventis U.S. LLCMultaq | $54 | $28,46518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Phoenix
- Paul SorajjaPhoenix$8.8M
- Timothy ByrnePhoenix$2.1M
- Mohamad LazkaniPhoenix$1.1M
- Parminder SinghPhoenix$854K
- Akil LoliPhoenix$506K
- Haidar YassinPhoenix$457K
- Michael WhitePhoenix$417K
- Nezar FallujiPhoenix$348K
- Floyd FortuinPhoenix$263K
- Nishant GuptaPhoenix$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.